Urothelial Carcinoma | Norton Healthcare

Indication: Urothelial Carcinoma

A Phase Ib/II Open Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Locally Advanced Or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy (MORPHEUS-mUC)

Patients with locally advanced or metastatic

Sub-indication: Multiple immunotherapy-based treatment combinations in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma

Line of Therapy: 2nd or 3rd Line

Drug Study

Principal Investigator: Chandler Park, M.D.
Norton Cancer Institute

Sponsor: F. Hoffmann-LaRoche Ltd.

Learn more at ClinicalTrials.gov

Email for more information: GU-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.